Navigation Links
Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Date:5/5/2008

ed their child's pain

as significantly lower than parents of children receiving the sham

placebo device (p<0.001).(1)

Zingo was found to be well tolerated in this patient population, with no serious drug-related adverse events reported. The most common skin assessment findings were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. The incidence of adverse events with Zingo was no higher than with sham placebo.(1) Demographic characteristics and sites of administration were evenly distributed across treatment groups.

The U.S. Food and Drug Administration (FDA) approved Zingo last year for children three to 18 years of age based on the results of the COMFORT-003 study and a second large clinical trial, COMFORT-004, which also found that use of Zingo was related to significantly less peripheral venous access procedural pain in children.

About Zingo and Venous Access Procedures

Zingo is a needle-free system that delivers lidocaine powder into the skin and provides analgesia in one to three minutes after administration.

In clinical trials, Zingo was well-tolerated. The most common adverse reactions in clinical trials were erythema, petechiae, and edema at the site of administration.(7) Full prescribing information is available at http://www.anesiva.com/img/ZingoPackage.pdf.

In addition to the hospital population, opportunities exist for Zingo in children in hemodialysis centers, as well as physicians' offices and clinical laboratories. In March, Anesiva submitted a supplemental New Drug Application with the U.S. Food and Drug Administration to expand the indication for Zingo to treat the pain associated with peripheral IV insertions and blood draws in adults.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
2. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
3. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
7. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
8. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
10. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
11. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2Alimera Sciences To Release Second Quarter 2014 Results 2
... A new approach to unblocking heart arteries minimally invasively ... and less risk overall, particularly for obese patients, according ... Symposium on Endovascular Therapy (ISET). Every year, about one ... open their blocked arteries. New data suggests that beginning ...
... Excalibur, the international,investment house specialising in medical ... to deliver pioneering stem cell treatments if it ... , Professor Sir Christopher ... that ReNeuron plc has received approval from the ...
Cached Medicine Technology:Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2UK Must Maintain its Momentum in Stem Cell Expertise 2
(Date:7/24/2014)... Kathleen Doheny HealthDay Reporter ... of obese children often don,t view their kids as unhealthy ... according to a new study. The children of the ... clinic at the Hasbro Children,s Hospital in Providence, R.I. ... good," said study researcher Dr. Kyung Rhee, now an assistant ...
(Date:7/24/2014)... treatment of overweight and obese preschoolers works better when ... only the child is targeted, according to research published ... the University at Buffalo and Women and Children,s Hospital ... or obese and had one parent who participated in ... to body mass index (BMI) measurements, calculated based on ...
(Date:7/24/2014)... like a medical device or surgical implant is put ... to Northwestern University,s Guillermo Ameer, most of the time, ... function. , "You will always get an inflammatory response ... in Northwestern,s McCormick School of Engineering and Applied Science ... Medicine. "A problem with commonly used plastic materials, in ...
(Date:7/24/2014)... Horizon BCBSNJ’s second annual “Back to ... a rent-free week in a beautiful Lavallette shore house, ... miss your chance to win a week’s vacation at ... New Jersey residents, 25 or older.* Residents can enter ... . , “A family vacation at the Jersey ...
(Date:7/24/2014)... IA (PRWEB) July 24, 2014 Members of ... Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, ... Governor appointed him to the Board and that his peers ... “I want to provide the best I can for the ... I am uniquely positioned to provide a special insight to ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... the numbers of heart transplants are on the decline. This ... properly//. Hence the doctors at the Papworth Hospital in Cambridge ... for five hours after it was removed from the donor. ... transplant was Michael Burt, 58, a builder from Burnham Market, ...
... US –based research has given hopes that researchers will be ... in the ears of humans challenged by deafness//. ,These tiny ... is then translated by the brain into sound. Once ... in permanent hearing loss. , ,Approximately, one out of every ...
... studies by Canadian researchers show that the male ... that are not recognized and understood// many health ... researchers found that though both male and female ... anxieties and fears about their encounters with health ...
... standards officers have issued a warning to the public that ... prescription drugs through the Internet//. , , Drugs such as ... have often turned out to be fakes or ... partaking of drugs without a prescription can turn ...
... the 23rd June recalled almost around 20,000 chocolate bars ... fears// that those bars may contain traces of salmonella. ... that there were minute traces of salmonella, which though ... the scientific standards for any hazards. The spokesperson had ...
... ahead of Sunday's game, after research has shown that the ... football matches. The game with Ecuador is the first knockout match ... BUPA said: "When people's emotions run high stress levels can shoot ... that history does not repeat itself”. "If England gets ...
Cached Medicine News:Health News:Latest In the Heart Transplant Field 2Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2
... 5500s electronic architecture incorporates advanced circuit designs ... it HI VUE an engineering philosophy ... to individual specifications while, at the same ... system. The end result is extraordinary performance ...
... endoscope with a built-in electronic scanning system. ... image under echo. It is also equipped ... observation. The EG-3630UR has achieved the highest ... well as exceptional ultrasound imaging capability. The ...
... is an affordable solution for low volume ... test menu includes a variety of clotting ... The ACL 1000 also offers bar code ... lab. Plus, it's backed by superior technology ...
... CX4-S system consolidates DATs, TDMs ... one workstation, targeted to the ... samples per day. Like all ... CX4-S is easy to use, ...
Medicine Products: